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The biogenesis of lipid droplets (LD) induced by serum
depends on group IVA phospholipase A2 (cPLA2). This work
dissects the pathway leading to cPLA2 activation and LD bio-
genesis. Both processes were Ca2-independent, as they took
place after pharmacological blockade of Ca2 transients elicited
by serum or chelation with 1,2-bis(2-aminophenoxy)ethane-
N,N,N,N-tetraacetic acid tetrakis(acetoxymethyl ester). The
single mutation D43N in cPLA2, which abrogates its Ca2
binding capacity and translocation tomembranes, did not affect
enzyme activation and formation of LD. In contrast, the muta-
tion S505Adid not affectmembrane relocation of the enzyme in
response to Ca2 but prevented its phosphorylation, activation,
and the appearance of LD. Expression of specific activators of
different mitogen-activated protein kinases showed that phos-
phorylation of cPLA2 at Ser-505 is due to JNK. This was
confirmed by pharmacological inhibition and expression of a
dominant-negative form of the upstream activator MEKK1. LD
biogenesis was accompanied by increased synthesis of ceramide
1-phosphate. Overexpression of its synthesizing enzyme cer-
amide kinase increased phosphorylation of cPLA2 at Ser-505
and formation of LD, and its down-regulation blocked the phos-
phorylation of cPLA2 and LD biogenesis. These results dem-
onstrate that LD biogenesis induced by serum is regulated by
JNK and ceramide kinase.
Intracellular lipid droplets (LD)5 are cytosolic inclusions
present in most eukaryotic cells, containing a core of triacyl-
glycerols (TAG) and cholesteryl esters, surrounded by a phos-
pholipid monolayer and by specific proteins, among which
the best characterized belong to the perilipin family (1–3). In
the last few years, the biology of LD has received increasing
interest, due to the close relationship between an excess of
lipid storage in certain tissues and pathologies such as obe-
sity, diabetes, or atherosclerosis (3–5). Cellular stress has
been related to the generation of LD, which might play a
cytoprotective role (6, 7). Therefore, dissecting the signaling
pathways leading to LD formation may have important clin-
ical applications in metabolic diseases and also in neurode-
generative diseases such as Parkinson and Alzheimer disease
(8, 9).
Cells generate LD from exogenous sources, free fatty acids or
lipoproteins, but LD also appear in the absence of external
lipids when cells are under stress, apparently after the recycling
of membrane phospholipids into TAG (7). We have shown
recently that group IVAPLA2 (also termed cPLA2) is required
for LD biogenesis either after exogenous lipid loading (10) or
during stress (7). Regardless of the LD-inducing situation, the
enzyme is not involved in the synthesis of neutral lipids; rather,
it allows the formation of LD from TAG-containing mem-
branes. cPLA2 can be activated by several mechanisms
(reviewed in Refs. 11, 12). It contains a Ca2 binding domain
(C2) that allows interaction with membrane phospholipids in
response to increased intracellular Ca2 concentrations, and the
single substitution D43N in this domain abrogates the Ca2-
dependent translocation of cPLA2 to membranes (13–15).
However, the increase of intracellular Ca2 is not universally
required, as several reports have shown cPLA2 activation in
vivo under resting Ca2 conditions (13, 16–19). In this regard,
anionic phospholipids like phosphatidylinositol 4,5-bisphos-
phate (PtdIns-4,5-P2) (20, 21) and ceramide 1-phosphate (Cer-
1-P) (22–25) bind specific regions of the enzyme and decrease
its Ca2 requirement to interact with membranes. Also, phos-
phorylation of cPLA2 at Ser residues 505, 515, and 727 appears
to play a role in enzyme activation (11, 12). Among these sites, it
is generally accepted that Ser-505 is the one that leads to
increased catalytic activity (26), and phosphorylation of Ser-
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505 depends on MAPK, among which most reports implicate
ERK and p38 (11, 12).
Recently, we have shown that phosphorylation of cPLA2 at
Ser-505 is key for LD biogenesis, as evidenced by the inability of
the S505A mutant to recapitulate the effect of the endogenous
enzyme (10). This work was undertaken to delineate the mech-
anism of cPLA2 activation that generates LD in the cell after
serum addition. In essence, we show that the activation of
cPLA2 is independent of increases of intracellular Ca2; fur-
thermore, we identify JNK as the MAPK implicated in cPLA2
activation. Finally, we show that ceramide kinase (CERK), the
enzyme responsible for the synthesis of Cer-1-P, mediates LD
biogenesis by inducing the phosphorylation of cPLA2 by JNK.
EXPERIMENTAL PROCEDURES
Materials—Nile red, primuline, trypsin, U73122, and Cer-
1-P were from Sigma. SP600125, SB20358, PD98059, and
N-acetyl-D-sphingosine (C2-ceramide) were from Calbio-
chem; and methylarachidonyl fluorophosphonate (MAFP)
was from Cayman Chemical Co. [5,6,8,9,11,12,14,15-3H]Arachi-
donic acid ([3H]AA) (200 Ci/mmol) was purchased from Ameri-
can Radiolabeled Chemicals, and [9,10-3H]palmitic acid (49
Ci/mmol) from Amersham Biosciences. Opti-MEM was from
Invitrogen. Rabbit anti-cPLA2, anti-phospho-Ser-505-cPLA2,
anti-JNK, anti-phospho-Thr-183/Tyr-185-JNK, anti-p38, anti-
phospho-Thr-180/Tyr-182-p38, anti-p44/42, and anti-phospho-
Thr-202/Tyr-204-p44/p42 antibodies were from Cell Signaling;
chicken anti-ADRP was from GenWay Biotech; rabbit anti-glyc-
eraldehyde-3-phosphate dehydrogenase was from Ambion, and
rabbit anti-CERK fromAbcam.
Cells—CHO-K1 cells were cultured in Ham’s F-12 medium
(Sigma) containing 7.5% fetal bovine serum (FBS, from Sigma),
100 units/ml penicillin, and 100 g/ml streptomycin (both
from Invitrogen). Cell passages were made once a week by
trypsinization. For the experiments, cells were seeded at a den-
sity of 30,000 cells/ml in 24-well (0.5 ml) or 6-well plates (2 ml)
andmaintained in FBS-containingmedium during 48 h. Before
LD induction, cells were switched to serum-free culture me-
dium for 24 h to set control conditions with minimal occur-
rence of LD (7). When indicated, cells (40–70% confluence)
were transfected with 1 g of plasmid/ml using Lipofectamine
PlusTM, following the manufacturer’s instructions.
Nile Red Staining and Fluorescence Microscopy—Cells cul-
tured on glass bottom culture dishes were washed with phos-
phate-buffered saline, fixed with 3% paraformaldehyde for 10
min, and washed twice with phosphate-buffered saline. Cells
were overlaid with 0.5 ml of phosphate-buffered saline, to
which 2.5 l of a stock solution of Nile red in acetone (0.2
mg/ml) were added, so the final concentrations of Nile red and
acetonewere 1g/ml and 0.5%, respectively. Sampleswere kept
in the dark until photographed in a Leica Qwin 500microscope
with a Leica DC200 camera, using the Leica DCviewer 3.2.0.0
software.
Flow Cytometry—Indirect quantification of LD by flow
cytometry in Nile red-stained cells was performed as described
previously (7, 10). Briefly, paraformaldehyde-fixed cells were
stained with 1 g/ml Nile red during 45 min and analyzed with
a Cytomics FC 500 (Beckman Coulter) equipped with an argon
laser (488 nm), in the FL1 channel (505–545 nm). After gating
out cellular debris, 30,000 events were acquired in all the assays,
in linear scale. Fluorescence intensities were quantified as the
median value of each distribution of events.
[3H]Arachidonic Release—Stimulated [3H]AA release from
cells, which is an estimate of cPLA2 activity, was measured as
described (7, 10, 27).
Ca2 Imaging—Cells grown onto polylysine-coated cover-
slips were incubated with the Ca2 indicator Fura-2/AM at 4
M in Krebs buffer of the following composition (in mM): 119
NaCl, 4.75 KCl, 5 NaHCO3, 1.2 MgSO4, 1.18 KH2PO4, 1.3
CaCl2, 20 Hepes, and 5 glucose, pH 7.4. After 1 h, cells were
washed and coverslips mounted in a static chamber on an
inverted Nikon TE2000U microscope with a conventional epi-
fluorescence system. Cells were excited alternatively at 340 and
380 nm, and emission light was collected at 510 nm every 4–10
s using a 12-bit CCD ERG ORCA Hamamatsu camera. Ratio
image of cells was analyzed using the Metafluor software (Uni-
versal Imaging). 14–20 cells were analyzed in each experiment.
Western Blots—Cells were lysed with 62.5 mM Tris-HCl
buffer, pH 6.8, containing 2% SDS, 10% glycerol, 50 mM di-
thiothreitol, and 0.01% bromphenol blue, and around 20 g
of protein were separated by standard 10% SDS-PAGE and
transferred to nitrocellulose membranes. Primary (1:1,000)
and secondary antibodies (1:5,000) were diluted in 25 mM
Tris-HCl buffer, pH 7.4, containing 140mMNaCl, 10% defat-
ted dry milk, 0.1% bovine serum albumin, and 0.1% Tween
20. Antibody binding was detected using the ECL detection
kit (Amersham Biosciences) and visualized using a Gene-
Genome HR chemiluminescence detection system coupled
to a CCD camera or with high performance chemilumines-
cence films (Amersham Biosciences).
siRNA Transfection—We used three short interfering RNA
(siRNA) duplexes fromGene Link, targeting accession number
NM_022766 (human CERK mRNA): CERK1-(537), CERK2-
(1377), and CERK3-(1679), with the following sequences: 5-
GGACAAGGCAAGCGGATAUTT (sense) and 5-TTCC-
UGUUCCGUUCGCCUAUA (antisense) for siRNA CERK1;
5-CGGAAAUGCUCCAGGUUCATT (sense) and 5-TTGC-
CUUUACGAGGUCCAAGU (antisense) for siRNA CERK2;
and 5-ACGAGGAAUUGAAGAGAAUTT (sense) and 5-
TTUGCUCCUUAACUUCUCUUA (antisense) for siRNA
CERK3. Cells were transfected at 60% confluence with 30 nM
siRNA, by adding to each 35-mm culture well 1 ml of Opti-
MEM (Invitrogen) containing 1.5 l of the stock siRNA solu-
tion (20 M) and 5 l of Lipofectamine PlusTM (1 mg/ml, from
Invitrogen). After 5 h, 1 ml of Ham’s F-12 medium containing
7.5% FBS was added, and the cells were incubated for 72 h and
then changed to serum-free medium during 24 h prior to treat-
ments.When appropriate, labeling with [3H]palmitate to mon-
itor the formation of Cer-1-P was done in the last 24 h.
Formation of [3H]Cer-1-P—[3H]Palmitate-prelabeled cells
were stimulated with 7.5% FBS during 15min, harvested on ice,
washedwith 1ml of phosphate-buffered saline, and centrifuged
prior to extraction of lipids (28). To separate Cer-1-P, 0.2-ml
aliquots of the chloroform phases were evaporated under vac-
uum, dissolved in 15 l of chloroform/methanol (3:1, v/v), and
spotted onto Silica Gel G thin layer chromatography plates
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(Merck), which were developed once in chloroform/methanol/
water (67.5:28.4:4, v/v) and three times in hexane/diethyl ether/
formic acid (55:45:1, v/v). After stainingwith primuline spray (5
mg of primuline in 100 ml of acetone/water (80:20, v/v), iden-
tification of ceramide and ceramide 1-phosphate was made by
co-migration with authentic standards. To quantify [3H]Cer-1-
P, silica in regions of theTLCplates co-migratingwith standard
Cer-1-P was scraped into vials, which after addition of scintil-
lation mixture were counted in a Tri-Carb 2810TR
(PerkinElmer Life Sciences) at 40% efficiency.
Confocal Microscopy—Transiently transfected CHO-K1
cells were treated for 10 min with 5 M ionomycin. Tomonitor
relocation of EGFP-cPLA2, EGFP-D43N-cPLA2, or EGFP-
S505A-cPLA2, images were acquired every 60 s with a Leica
TCS SP2 AOBS confocal microscope.
Constructs—The construct encoding for the expression of a
fusion protein containing N-terminal enhanced green fluores-
cent protein followed by the entire sequence of the human
cPLA2 (EGFP-cPLA2) was described elsewhere (21, 27).
Those for EGFP-D43N-cPLA2 and EGFP-S505A-cPLA2
were described in Refs. 27 and 10, respectively. Transfection of
pGFP-C3 (Clontech) was used as control. Constructs pCMV5-
MEKK1 and pSR-K432M-MEKK1, encoding constitutively
active and dominant-negative forms of MEKK1, respectively,
were kindly provided by Dr. Pura Mun˜oz-Ca´noves (Centre de
Regulacio´ Geno`mica, Barcelona, Spain). Constructs pCMV5-
myc-MEKK3-EE and pcDNA3-MEK1-EE, encoding constitu-
tively active MEKK3 and MEK1, were gifts from Dr. Ana
Cuenda (Centro Nacional de Biotecnología, Consejo Superior
de Investigaciones Científicas-Universidad Auto´noma de
Madrid, Madrid, Spain) and Dr. Piero Crespo (Instituto de
Investigaciones Biome´dicas, Consejo Superior de Investigacio-
nes Científicas-Universidad de Cantabria, Santander, Spain),
respectively. The construct for CERK expression (pcDNA3.1
HisTOPO-hCERK) is described elsewhere (29).
Statistical Analysis—Data analysis was carried out with
Prism software (GraphPad). Responses among different treat-
ments were analyzed with one-way analysis of variance fol-
FIGURE 1. FBS activates cPLA2 and induces LD biogenesis in the presence of BAPTA-AM or U73122. A, Ca2 responses of serum-starved, fura-2/AM-
loaded CHO-K1 cells under control conditions (continuous line) or after pretreatment with 45 M BAPTA-AM (circles) or 10 M U73122 (triangles) for 30 min
before fluorescencemeasurements were started. At the time indicated, 7.5% FBSwas added. B and C, Western blots of serum-starved CHO-K1 pretreatedwith
45M BAPTA-AMor 10MU73122 during 30min and then stimulatedwith 7.5% FBS for 15min (B) or 6 h (C).D, cPLA2 activitymeasured after the radioactivity
was released to the medium of serum-starved CHO-K1 cells that had been prelabeled during 24 h with 0.5 Ci/ml [3H]arachidonic acid, then washed, and
treated with 45 M BAPTA-AM, 10 M U73122, and/or 10 M MAFP for 30 min before a 15-min stimulation with 7.5% FBS. E, indirect quantification of LD in
serum-starved CHO-K1 cells that had been pretreated for 30min with 10M U73122 and/or MAFP and then stimulated with 7.5% FBS for 6 h. Cells were fixed
and stained with Nile red to quantify LD by flow cytometry. Fluorescence intensities in FL1 were quantified as the median values of each event distribution.
Results in C and D are means S.E. of three independent experiments. *, significantly different (p 0.01) from controls.
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lowed by Bonferroni’s multiple comparison test. All experi-
ments were carried out with determinations in triplicate. Most
results are presented as means  S.E. of three independent
experiments, except those in Fig. 8B, which are means range
of two experiments. Results shown as fluorescence Ca2 sig-
nals, Western blots, or microphotographs are representative of
at least three independent experiments with essentially the
same outcome.
RESULTS
Activation of cPLA2Required for LDBiogenesis Is Independ-
ent of Ca2—Serum-starved cells challenged with 7.5% FBS
produced transient Ca2 increases (Fig. 1A). As expected, this
Ca2 signal disappeared when cells were pretreated with 45M
BAPTA-AM during 30 min prior to stimulation with FBS (Fig.
1A). The inhibitory effect of BAPTA-AM was confirmed after
the inability of ionomycin to induce a Ca2 response (data not
shown). cPLA2 was phosphorylated upon FBS stimulation
when intracellularCa2 increaseswere abrogatedbyBAPTA-AM
(Fig. 1B), and in fact, cPLA2 activity, measured as [3H]AA
release to the medium, was unaffected by intracellular Ca2
chelation (Fig. 1D). This Ca2-chelating strategy was toxic over
6 h, however, and did not allow us to measure LD levels, which
we usually monitor after a 6-h treatment (7, 10). Instead, we
used the phosphoinositide phospholipase C inhibitor U73122
to block the Ca2 signals induced by FBS, which are due to the
generation of inositol 1,4,5-trisphosphate (30). As shown in Fig.
1A, pretreatment with 10 M U73122 blocked the Ca2
response, but it did not affect phosphorylation of cPLA2 at
Ser-505 (Fig. 1C) or [3H]AA releasing activity (Fig. 1D). Impor-
tantly, in the presence of the phospholipase C inhibitor, FBS
still promoted ADRP expression (Fig. 1C) and LD biogenesis
that was sensitive to the cPLA2 inhibitor MAFP (Fig. 1E).
Additional evidence for a Ca2-independent activation of
cPLA2 during LD biogenesis came from the transfection of a
D43N-cPLA2 mutant. Asp-43 resides in the Ca2-binding
loop 1 at the membrane binding face of the C2 domain of the
enzyme and participates in the coordination of the two Ca2
ions that drivemembrane binding (11). Substitution of this res-
idue for Asn increases 100-fold the Ca2 requirement for activ-
ity in vitro (31), and it prevents translocation of the enzyme to
membranes in response to Ca2 ionophores (15, 27). In agree-
ment with this, EGFP-D43N-cPLA2 did not relocate in
CHO-K1 cells stimulated with 5M ionomycin, unlike the wild
type enzyme, which translocated to perinuclear membranes
and structures resembling the Golgi apparatus (Fig. 2,A–D). In
contrast, EGFP-S505A-cPLA2, which lacks the Ser-505 phos-
phorylation site but retains its Ca2 binding capacity, translo-
cated to membranes in response to ionomycin just as the wild
type enzyme (Fig. 2, E and F). Importantly, FBS treatment
induced phosphorylation of wild type and D43N cPLA2, at
Ser-505 (Fig. 2G). Furthermore, transfection of EGFP-D43N-
cPLA2 resulted in increased release of [3H]AA (Fig. 2H), both
under basal conditions and upon FBS stimulation, to the same
levels achieved by transfection of EGFP-cPLA2. Regarding LD
occurrence, the effect of the D43N mutant was identical to the
wild type enzyme; there was a 2.5-fold increase of LD upon FBS
stimulation, monitored either by flow cytometry (Fig. 2I),
ADRP content (data not shown), or by fluorescencemicroscopy
(Fig. 2, J andK). Taken together, these results demonstrate that
the activation of cPLA2 and biogenesis of LD induced by FBS
are independent of Ca2 and do not require massive relocation
of the enzyme. Furthermore, the results confirm our previous
finding that phosphorylation of cPLA2 at Ser-505 is essential
for its activation by FBS, although there is no apparent reloca-
tion in response to the faint Ca2 signal elicited by the stimulus
(10).
JNK, but Not ERK or p38 MAPK, Is Responsible for cPLA2
Phosphorylation and LD Biogenesis—cPLA2 is phosphoryla-
ted at Ser-505 by MAPKs (11, 12), and to dissect the pathway
during LD biogenesis, we monitored JNK, p38, and ERK
MAPKs at different times after FBS replacement. As shown in
Fig. 3, all threeMAPKs became activated after stimulation with
7.5% FBS. We therefore activated each MAPK individually by
transfecting constitutively active upstream activators of each
pathway. As shown in Fig. 4A, transfection of the catalytic
domain of MEKK1, which encodes a constitutively active
kinase (MEKK1), induced phosphorylation of JNK in the
FIGURE 2. EGFP-D43N-cPLA2 is as effective as EGFP-cPLA2 to induce LDbiogenesis in response to FBS. A–F, CHO-K1 cells were transiently transfected
with plasmids encoding EGFP-cPLA2 (A and B), EGFP-D43N-cPLA2 (C and D), or EGFP-S505A-cPLA2 (E and F). Confocal images were obtained before (A, C,
and E) or 10 min after addition of 5 M ionomycin. G, Western blots of total cPLA2 and phospho-Ser-505-cPLA2 of transiently transfected cells. H, [
3H]AA
release from serum-starved CHO-K1 cells transfected with EGFP-cPLA2, EGFP-D43N-cPLA2, or EGFP-S505A-PLA2 and kept unstimulated (open bars) or
stimulated with 7.5% FBS for 15min (filled bars). I, indirect quantification of LD by flow cytometry in cells after 6 h under control conditions (open bars) or with
7.5% FBS (filled bars). J and K, serum-starved CHO-K1 cells transiently transfectedwith EGFP-D43N-cPLA2 (J) or with EGFP-S505A-PLA2 (K) were stainedwith
Nile red for epifluorescence microscopy. Results in H and I are means S.E. of three independent experiments. *, significantly different (p 0.01) from green
fluorescent protein-transfected cells; #, significantly different (p 0.01) from FBS-stimulated, green fluorescent protein-transfected cells.
FIGURE 3. FBS induces the phosphorylation of JNK, p38, and ERK in
CHO-K1cells.Serum-starvedCHO-K1cellswere treatedwith7.5%FBS for the
indicated times. Total andphosphorylated JNK, p38, andERKweremonitored
by Western blot.
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absence of FBS stimulus, but not of ERK, and only a slight
increase of p38. Likewise, transfection of MKK3EE and
MEK1EE resulted in the specific phosphorylation of p38 and
ERK, respectively, in the absence of FBS. Importantly, only the
activation of JNK increased phosphorylation of cPLA2 at Ser-
505 (Fig. 4A), and this was inhibited in the presence of the JNK
inhibitor SP600125 at 10 M (data not shown). MEKK1-JNK-
mediated phosphorylation of cPLA2 was mirrored by an
increased [3H]AA-releasing activity in the absence of FBS stim-
ulus, which again was inhibited by SP600125 and also byMAFP
(Fig. 4B). In contrast, [3H]AA released from cells transfected
either withMKK3EE orMEK1EEwas not different from that in
control cells (Fig. 4B). In close agreement with data on cPLA2
phosphorylation and activity, Fig. 4C shows that cells trans-
FIGURE 4. Activation of JNK, but not of p38 or ERK, is sufficient to phos-
phorylate cPLA2 and induce LD biogenesis in the absence of FBS.
CHO-K1 cells were transiently transfected with plasmids encoding MEKK1,
MEKK3EE, or MEK1EE and switched to culture medium without FBS. A, phos-
phorylation of JNK, p38, ERK, and cPLA2 in the absence of FBS. B, cells were
prelabeled with 0.5 Ci/ml [3H]AA during 24 h and then washed, and the
release of radioactivity to themediumwas quantified after 15min. C, indirect
quantification of LD by flow cytometry. Results in B and C aremeans S.E. of
three independent experiments. *, significantly different (p  0.01) from
control.
FIGURE 5. JNK inhibitor SP600125 prevents cPLA2 activation and LD
biogenesis induced by FBS. Serum-deprived CHO-K1 cells were pretreated
for 30minwith 10M concentrations of SP600125, SB20358, or PD98059 and
then challengedwith 7.5% FBS for 15min (B) or 6 h (A and C).A,Western blots
of total cPLA2, phospho-Ser-505-cPLA2, and ADRP. B, radioactivity re-
leased from serum-deprived CHO-K1 cells that were prelabeled during 24 h
with 0.5Ci/ml [3H]AA, washed, and pretreatedwith drugs for 30min before
a 15-min stimulationwith 7.5%FBS.C, serum-starved cellswere treated for 30
min with drugs, then stimulated with FBS during 6 h, fixed, and stained with
Nile red to quantify LD by flow cytometry. Results in B and C aremeans S.E.
of three independent experiments. *, p 0.01 compared with control in the
absence of FBS; #, p 0.01 compared with FBS-treated cells.
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fected with MEKK1 had increased LD content as monitored
by flow cytometry. In contrast, stimulation of p38 or ERK did
not induce the formation of LD. Again, LD biogenesis induced
by expression of MEKK1 in the absence of FBS stimulus was
sensitive to inhibition by SP600125 and MAFP.
The preceding results show that the JNK inhibitor SP600126
antagonizes the activation of cPLA2 and the biogenesis of LD
in the absence of an FBS stimulus. To validate this pharmaco-
logical evidence in a more physiological setting, we compared
the ability of MAPK inhibitors to block cPLA2 activation and
LD biogenesis induced by FBS. As shown in Fig. 5A, phosphor-
ylation of cPLA2 induced by 7.5% FBS was inhibited in the
presence of 10MSP600125, but it was not affected by the same
concentration of the p38 inhibitor SB20358 or theMAPK/ERK
kinase inhibitor PD98059. In close agreement with these
results, [3H]AA release stimulated by FBSwas only decreased in
the presence of the JNK inhibitor but was unaffected by
SB20358 or PD98959 (Fig. 5B). Furthermore, the occurrence of
LD induced by FBS, monitored either by flow cytometry (Fig.
5C) or after the expression ofADRP (Fig. 5A), was sensitive only
to the JNK inhibitor.
We also inhibited JNK by transfecting a dominant-negative
form of MEKK1, the upstream activator of JNK. Fig. 6A shows
that phosphorylation of JNK in response to FBS stimulationwas
partially inhibited in cells transfected with K432M-MEKK1, as
compared with cells transfected with empty vector. The partial
inhibition of JNK was enough to fully inhibit cPLA2 phos-
phorylation induced by FBS (Fig. 6A). In close agreement with
this, cPLA2 activity monitored after the release of [3H]AA
(Fig. 6B) and LD biogenesis measured by flow cytometry (Fig.
6C) were clearly inhibited by transfection of K432M-MEKK1.
Results on the inhibition of LD were confirmed by ADRP
expression levels (data not shown) and by fluorescence micro-
scopy. Fig. 6, D and E, shows that, unlike cells transfected with
empty vector, which generate LD after FBS replacement, those
transfected with K432M-MEKK1 do not contain LD. Taken
together, these results demonstrate that the MAPK that acti-
vates cPLA2 during LD biogenesis is JNK.
Ceramide 1-Phosphate Induces LD Biogenesis in the Absence
of FBS—Next, we assessed the possible implication of Cer-1-P
in cPLA2 activation in our system. Cer-1-P drives the translo-
cation of cPLA2 to membranes and is absolutely required for
FIGURE 6. Transfection of a dominant-negative form ofMEKK1 (K432M-MEKK1) inhibits JNK phosphorylation, activation of cPLA2, and LD biogen-
esis.CHO-K1 cells were transfectedwith empty vector or vector encoding K432M-MEKK1. Cells were serum-starved for 24 h and then challenged for 15min (A
and B) or 6 h (C) with 7.5% FBS. A, phosphorylation levels of JNK and cPLA2. B, radioactivity released from cells that had been prelabeled during 24 h with 0.5
Ci/ml [3H]AA. C, indirect quantification of LD by flow cytometry.D and E, cells were transfectedwith empty vector (D) or with vector encoding K432M-MEKK1
(E), stimulated for 6 h with 7.5% FBS, and stained with Nile red for epifluorescence microscopy. Results in B and C are means  S.E. of three independent
experiments. *, significantly different (p 0.01) from control.
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its activation in response to inflammatory agonists (25), but it
also might contribute to the phosphorylation state of the
enzyme (32). We treated serum-starved cells with 2.5 M Cer-
1-P in ethanol/dodecane (98:2) at a final vehicle dilution of
1:1000 (33). Cer-1-P induced both JNK and cPLA2 phosphor-
ylation (Fig. 7A). Also, Cer-1-P stimulated the release of
[3H]AA in an SP600125- andMAFP-sensitive fashion, to lev-
els that were similar to those attained with FBS stimulation
(Fig. 7B). In contrast to Cer-1-P, C2-ceramide at the same
concentration did not affect JNK and cPLA2 phosphoryla-
tion or cPLA2 activity. In agreement with these results,
Cer-1-P induced LD biogenesis that was inhibited by
SP600125 and MAFP (Fig. 7C). LD quantification with flow
cytometry agreed with ADRP expression levels and epifluo-
rescence microscopy (data not shown). To confirm results
on exogenously supplied Cer-1-P, we overexpressed CERK,
the enzyme responsible for Cer-1-P synthesis. Expression of
CERK in CHO-K1 cells induced the phosphorylation of JNK
and cPLA2 (Fig. 7D). Furthermore, the synthesis of Cer-1-P
was enhanced, and this was accompanied by the stimulation
FIGURE 7. Cer-1-P and CERK stimulate cPLA2 and induce LD biogenesis. A, Western blots of phospho-JNK and phospho-cPLA2 from serum-starved
CHO-K1 cells that were treated with vehicle, 2.5 M C2-ceramide, 2.5 M Cer-1-P, or 7.5% FBS for 15 min. B, radioactivity released from [
3H]AA prelabeled,
serum-starved cells that were pretreated for 30minwithMAFP or SP600125, then stimulated for 15minwith C2-Cer, Cer-1-P, or FBS. C, quantification of LD by
flowcytometry after a 6-h treatmentwithC2-Cer andCer-1-P of FBS.D–G, cellswere transiently transfectedwith aplasmid encodingCERKand thenmaintained
in the absence of FBS. Overexpression of CERK increased the phosphorylation of JNK and cPLA2 (D). CERK-transfected cells were prelabeled for 24 h with
[3H]palmitate orwith [3H]AA tomonitor synthesis of Cer-1-P (E) and cPLA2 activity (F), respectively. CERK also increasedbasal levels of LD in the absenceof FBS
(G). *, significantly different (p 0.01) from control.
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of cPLA2 activity and the biogenesis of LD (Fig. 7, E–G).
These results indicate that an increase of Cer-1-P can induce
LD formation through JNK activation and subsequent
cPLA2 phosphorylation at Ser-505.
FBS Increases Cer-1-P, and Silenced Expression of CERK
Inhibits the Formation of LD Induced by FBS—To tackle the
relevance of the latter set of results, we knocked down the
expression of CERKwith an siRNA approach. Among the three
different siRNA sequences used, two of them (siRNA CERK1
and siRNA CERK3) effectively down-regulated the enzyme,
whereas siRNA CERK2 had no effect (Fig. 8A). Fig. 8B shows
that FBS stimulation increased the synthesis of [3H]Cer-1-P in
[3H]palmitate-prelabeled cells, and this was blocked by siRNA
CERK1 and siRNA CERK3 but not by siRNA CERK2. We did
not observe changes in [3H]ceramide content under any condi-
tion (data not shown). CERK down-regulation also inhibited
the phosphorylation of JNK and cPLA2 induced by FBS (Fig.
8A). Furthermore, knocked down expression of CERK inhib-
ited [3H]AA release (Fig. 8C) and LD biogenesis monitored by
flow cytometry (Fig. 8D), ADRP
expression (Fig. 8A), or by
fluorescence microscopy (data not
shown). In conclusion, the above
results show that serum-induced
LD biogenesis is mediated by CERK
and formation of Cer-1-P.
DISCUSSION
This study addresses the mecha-
nism of cPLA2 activation needed
for the biogenesis of LD induced by
FBS. Our findings can be summa-
rized in three major points. First,
cPLA2 activation and LD biogene-
sis are independent of intracellular
Ca2 rises, with no apparent reloca-
tion of the enzyme. Second, JNK is
the MAPK that activates cPLA2 in
our experimental model. Third, the
Cer-1-P-generating enzyme CERK
is required for the activation of JNK,
and hence of cPLA2.
This study shows that the path-
way leading to cPLA2 activation
and LD biogenesis is Ca2-in-
dependent. Intracellular chelation
with BAPTA-AM or blocking of
the inositol 1,4,5-trisphosphate-in-
duced Ca2 transient elicited by
FBS does not alter cPLA2 activa-
tion and LD biogenesis. Moreover,
the single mutation D43N in the C2
domain of the enzyme, which abro-
gates its Ca2 binding capacity,
does not affect activity in response
to FBS. Several reports have estab-
lished the dispensability of Ca2
rises in terms of full enzyme activa-
tion in vivo (13, 16–19) while putting forward the requirement
of the signaling lipids PtdIns-4,5-P2 (17, 20, 21, 34) and Cer-1-P
to allow interaction with membranes (22–25). The D43N
mutation in cPLA2 renders the enzyme refractory to physio-
logical Ca2 concentrations (31), but it is fully active on PtdIns-
4,5-P2-containing micelles (34). We have not addressed the
possible role of PtdIns-4,5-P2 in LD biogenesis, but in light of
the present results this is certainly a goal in the near future. It is
now clear that cPLA2 activity is essential for the generation of
LD after TAG present in the endoplasmic reticulum (7, 10);
however, we have consistently found no enzyme transloca-
tion to the nuclear envelope and nearby membranes in
response to FBS (10). Bearing in mind that the D43N muta-
tion does not suppress interfacial activity of the C2 domain
(34), in our experimental model the enzyme could interact
with the diffuse endoplasmic reticulum membrane system
and/or nascent LD. This would probably escape detection in
our studies, which were carried out within minutes following
FBS stimulation (10).
FIGURE 8.CERK is required for the activation of JNK and cPLA2 and for LDbiogenesis.CHO-K1 cells were
transfectedwith three siRNA-CERK duplexes as described under “Experimental Procedures” andmaintained in
7.5%FBS-containingmediumduring72hand then inmediumwithout FBS for 24h.During these last 24h, cells
were prelabeledwith [3H]palmitate orwith [3H]AA tomonitor synthesis of Cer-1-P and cPLA2 activity, respec-
tively (B andC).A,Western blots showing that siRNA-CERK1 and siRNA-CERK3 knocked down the expression of
CERK, precluded phosphorylation of JNK and cPLA2 induced by a 6-h treatment with FBS, and decreased
ADRP content. B, [3H]palmitate-prelabeled cells were stimulated with FBS during 15 min. Lipid extracts were
separated by TLC, and areas co-migrating with Cer-1-P standard were scraped onto vials and counted.
C, [3H]AA-prelabeled cells were stimulated with FBS during 15 min, and radioactivity in the medium was
counted.D, cells were stimulated with FBS during 6 h, fixed, and stained with Nile red, and LDwere quantified
by flow cytometry. Results in C andD aremeans S.E. of three experiments. Results in B aremeans range of
two experiments. *, significantly different (p  0.01) from controls. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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Our results show that JNK regulates cPLA2 activation and
LD biogenesis by inducing phosphorylation at Ser-505.
Although phosphorylation at this site increases activity in vitro
only 2-fold (11), it confers increased membrane affinity at low
micromolarCa2 concentrations (11, 12), and this tighter bind-
ing to the lipid surface could become critical for enzyme acti-
vation under our resting Ca2 conditions. FBS activates ERK,
p38, and JNK, and we identify the JNK cascade as the one gov-
erning cPLA2 phosphorylation in our system. This also stands
probably for oleate-induced LD.6 A literature survey shows that
the identity of the MAPK cascade leading to the phosphoryla-
tion of cPLA2 at Ser-505 is a matter of cell type and triggering
stimulus, often involving ERK or/and p38 MAPK. However, to
our knowledge only two recent reports have uncovered a key
role of JNK in cPLA2 activation, both related to the microbi-
cidal activity of phagocytes. Lee et al. (35) showed that secretion
ofmonocyte chemoattractant protein-1 induced by stimulation
of macrophages with synthetic oligodeoxynucleotides contain-
ing CpG motifs depends on cPLA2 activity, which can be
blocked by pharmacological inhibition or down-regulation of
JNK. Casas et al. (36), on the other hand, showed that translo-
cation of cPLA2 to phagosomal membranes of macrophages,
an event required for eicosanoid generation and killing of the
ingested microbe, requires enzyme phosphorylation at Ser-505
and is blocked after pharmacological inhibition of JNK. There-
fore, this study describes for the first time the crucial role of the
JNK cascade in the activation of cPLA2 for LD biogenesis. We
showed previously that the implication of cPLA2 in LD bio-
genesis after serum lipoproteins is not unique to the Chinese
hamster ovary cell model (10). It remains to be established
whether this generalization also stands for JNK, as it may hold
promise for new pharmacological approaches in the treatment
of metabolic diseases. In this regard, LD have been shown to
interfere with membrane translocation of the insulin-sensitive
glucose transporter, an observation that might account for
insulin resistance in type 2 diabetes (5). Therefore, it is tempt-
ing to speculate that the observations that animal models of
obesity have abnormally elevated JNK activity and that JNK1
knock-outmice on obesity-inducing diets are protected against
adiposity and insulin resistance (37) are related to cPLA2-me-
diated formation of LD.
This study also presents CERK and its product Cer-1-P as
new key players in the biogenesis of LD. This is somehow not
surprising, as Cer-1-P is a firmly established activator of
cPLA2 (32, 38). Cer-1-P also has pro-survival effects (39), in
line with the protective role that LD play during nutrient star-
vation and other stress conditions (6, 7). Cer-1-P interacts with
the cationic -groove (Arg-57, Lys-58, and Arg-59) of the C2
domain of cPLA2. This enhances interactionwithmembranes
and lowers the EC50 for Ca2 down to 31 nM, resulting in
increased and catalytic activity in vitro (22, 24). Recently, it has
been described that CERK is required for cPLA2 activation
and translocation to the Golgi in response to Ca2 increases in
the cell (25). Our results clearly show the requirement of CERK
for cPLA2 activation and LD biogenesis. However, they do not
quite fit with a direct interaction of Cer-1-P and cPLA2. First,
cPLA2 activation for LD biogenesis is independent of Ca2,
and it does not require enzyme translocation to the nuclear
envelope and the Golgi. Second, our data show that CERK acti-
vates JNK and downstream phosphorylation of cPLA2 at Ser-
505. This suggests that Cer-1-P does not solely promote asso-
ciation of the enzyme with membranes. Our data fully support
a formerly proposedmechanism (32, 40) whereby Cer-1-P acti-
vates the JNK cascade, either directly or after the inhibition of
protein phosphatases 1 and 2A. This mechanism is in keeping
with our observation that okadaic acid induces LDbiogenesis in
a JNK- and cPLA2-dependent fashion.6 Regardless of the
mechanism, our results clearly point to CERK as a potential
target for the treatment of metabolic diseases.
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